NewAmsterdam Pharma’s USD181 Million Secondary Offering

De Brauw advised underwriters on secondary offering of shares in NewAmsterdam Pharma.NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at…